Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

A number of other equities research analysts have also issued reports on the company. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Jefferies Financial Group boosted their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a report on Monday, July 7th. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Finally, Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $439.58.

Alnylam Pharmaceuticals Trading Down 1.0%

NASDAQ:ALNY opened at $456.35 on Friday. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a fifty day simple moving average of $441.57 and a 200-day simple moving average of $339.95. The company has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period last year, the firm posted ($0.13) EPS. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This trade represents a 13.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock worth $44,160,261 in the last quarter. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $275,000. Strs Ohio acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $7,781,000. GAMMA Investing LLC increased its stake in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 77 shares during the period. Finally, Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.